Literature DB >> 6448665

The etiology of toxic peripheral neuropathies: in vitro effects of acrylamide and 2,5-hexanedione on brain enolase and other glycolytic enzymes.

R D Howland, I L Vyas, H E Lowndes, T M Argentieri.   

Abstract

The in vitro effects of the neurotoxic compounds, acrylamide and 2,5-hexanedione, on several glycolytic enzymes including enolase, phosphofructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and lactic dehydrogenase (LDH) were studied in rat brain. A differential sensitivity of the enzymes to the inhibitory effects of the neurotoxins was observed. The order of increasing sensitivity to 2,5-hexanedione was enolase -- GAPDH -- PFK and to acrylamide the order was PFK -- enolase -- GAPDH. Neither neurotoxin inhibited LDH. The inhibition of enolase by acrylamide exhibited a mixed type pattern in double reciprocal plots. The inhibition could be completely reversed by dialysis indicating that it did not involve covalent bond formation. In the presence of dithiothreitol (DTT) or glutathione the inhibition of enolase by either acrylamide or 2,5-hexanedione was potentiated. Activity of enolase inhibited by both acrylamide and DTT could not be restored to pre-inhibition rates following dialysis indicating that an irreversible interaction between acrylamide and enolase had taken place. The results suggest that neurotoxic compounds which produce distal axonopathies have a common pattern of attack on glycolytic enzymes and that interruption of glycolysis is the underlying biochemical basis for both the physiological and morphological damage caused by these compounds.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6448665

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Creatine kinase activities in brain and blood:possible neurotoxic indicator of acrylamide intoxication.

Authors:  M Matsuoka; H Matsumura; H Igisu
Journal:  Occup Environ Med       Date:  1996-07       Impact factor: 4.402

2.  Effects of chronic n-hexane exposure on nervous system-specific and muscle-specific proteins.

Authors:  J Huang; K Kato; E Shibata; K Sugimura; N Hisanaga; Y Ono; Y Takeuchi
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

3.  Neurofilament degradation in the nervous system of rats intoxicated with acrylamide, related compounds or 2,5-hexanedione.

Authors:  H Tanii; M Hayashi; K Hashimoto
Journal:  Arch Toxicol       Date:  1988-08       Impact factor: 5.153

4.  Quantitative alterations of S-100 protein and neuron specific enolase in the rat nervous system after chronic 2,5-hexanedione exposure.

Authors:  J E Karlsson; S Wang; L E Rosengren; K G Haglid
Journal:  Neurochem Res       Date:  1993-02       Impact factor: 3.996

5.  Effect of acrylamide and related compounds on glycolytic enzymes in rat sciatic nerve in vivo.

Authors:  J Sakamoto; K Hashimoto
Journal:  Arch Toxicol       Date:  1985-09       Impact factor: 5.153

6.  Inhibition of brain enolases by acrylamide and its related compounds in vitro, and the structure-activity relationship.

Authors:  H Tanii; K Hashimoto
Journal:  Experientia       Date:  1984-09-15

7.  Effect of 2,5-hexanedione and 3,4-dimethyl-2,5-hexanedione on retrograde axonal transport in sciatic nerve.

Authors:  M I Sabri
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

8.  Neurotoxicity of acrylamide and related compounds in rats. Effects on rotarod performance, morphology of nerves and neurotubulin.

Authors:  H Tanii; K Hashimoto
Journal:  Arch Toxicol       Date:  1983-11       Impact factor: 5.153

9.  Effect of acrylamide and related compounds on glycolytic enzymes in mouse brain in vitro.

Authors:  J Sakamoto; K Hashimoto
Journal:  Arch Toxicol       Date:  1985-09       Impact factor: 5.153

10.  Cytotoxicity of acrylamide and related compounds to mouse neuroblastoma and rat schwannoma cells.

Authors:  H Tanii; N Miki; M Hayashi; K Hashimoto
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.